Status and phase
Conditions
Treatments
About
The purpose of this study is to assess the safety and tolerability of intravenously delivered mesenchymal steml cells (MSC) in one of two fixed dosing regimens at two time points in patients with chronic kidney disease.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 30-80 years
Estimated glomerular filtration rate (eGFR) 25-55 ml/min/1.73m2
Hemoglobin A1c of ≤ 8% despite maximally tolerated anti-diabetes therapy
Ability to give informed consent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
14 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal